Group 1 - The company has completed the comprehensive review of its new drug, a chemical Class 1 oral medication for Alzheimer's disease, and is currently in the final review stage [2] - The company has provided all required professional research materials as part of the approval process, and all work is progressing normally [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]

Core Viewpoint - The company is currently conducting a Phase III clinical trial for its KH110 project, targeting patients aged 50 to 80 with mild to moderate Alzheimer's disease [2] Group 1 - The clinical trial is being carried out at multiple hospitals across the country [2] - The recruitment criteria for the trial specify that participants must be between the ages of 50 and 80 [2] - Information regarding the trial has been registered and made publicly available on the National Medical Products Administration's clinical trial registration platform [2] Group 2 - The company encourages interested individuals or their families to check the registration platform for specific inclusion criteria [2] - Participants are advised to visit nearby research hospitals for evaluation if they wish to join the trial [2]

Group 1 - The core viewpoint of the article revolves around the controversial acquisition of Green Valley Pharmaceutical by Fosun Pharma, which has raised significant skepticism due to the financial health of Green Valley and the uncertain future of its key product, GV-971, also known as "Jiuyiqi" [6][10][12]. - Fosun Pharma announced a plan to acquire Green Valley for 1.412 billion yuan, despite Green Valley's net assets being only approximately 10.36 million yuan, leading to concerns about the high premium paid for a company in financial distress [10][16]. - Green Valley's main product, Jiuyiqi, has faced production halts due to the expiration of its registration certificate, resulting in a significant drop in revenue and a net loss of 6.7 million yuan in the first three quarters of the year [10][16][18]. Group 2 - The article discusses the historical context of Green Valley's founder, Lu Songtao, and the controversies surrounding the company's previous products, which have contributed to skepticism about Jiuyiqi's efficacy and the company's credibility [20][26][30]. - Fosun Pharma's response to regulatory inquiries emphasizes their confidence in Jiuyiqi's potential, outlining a phased payment structure for the acquisition that allows for risk mitigation based on the drug's clinical trial outcomes [18][19]. - The market potential for Jiuyiqi is highlighted, with estimates suggesting a target population of approximately 3.56 million and a projected peak sales value of around 4 billion yuan by 2035 if the drug is successfully reintroduced to the market [33][34].

Core Viewpoint - Fosun Pharma is investing 14.12 billion yuan in Green Valley Pharmaceutical to acquire a controlling stake, aiming to integrate the Alzheimer's drug, Manluotena Capsules, into its innovative drug pipeline, enhancing its position in the Alzheimer's disease sector [2][7]. Group 1: Investment Details - The investment consists of acquiring existing equity (1.43 billion yuan) and subscribing to new registered capital (12.69 billion yuan) [3][8]. - The payment for the new registered capital will be made in installments, with the first payment of 6.35 billion yuan due on the closing date, and the remaining 6.35 billion yuan to be paid within three years based on the target company's R&D progress [4][8]. Group 2: Clinical Progress and Regulatory Issues - Manluotena Capsules received conditional approval from the National Medical Products Administration (NMPA) in November 2019 for treating mild to moderate Alzheimer's disease, becoming the first approved drug for this indication since 2002 [2][7]. - The drug has faced efficacy controversies, with criticisms regarding the validity of its research and changing mechanisms of action [2][7]. - Green Valley Pharmaceutical submitted a supplementary application to extend the drug's registration before its five-year validity expires in 2024, but the NMPA did not approve it due to incomplete post-marketing confirmatory clinical studies [2][7]. Group 3: Risk Management and Future Plans - Fosun Pharma conducted due diligence covering clinical, regulatory, patent, production, commercialization, financial, legal, human resources, and investment aspects of Green Valley and its main product [3][8]. - The company has implemented risk control measures, including the pledge of 10% of the acquired equity by the founder's entity to secure potential losses [4][8]. - The clinical trial design for the confirmatory study has been revised, extending the double-blind treatment period from 36 weeks to 48 weeks and increasing the sample size from 1,312 to 1,950 participants, with approval from the NMPA [9]. - As of December 15, 2025, 580 participants have been enrolled in the clinical study, with expectations to complete enrollment by the end of 2027 and submit a summary report to the NMPA in early 2029 [10].

Core Viewpoint - Fosun Pharma's proposed acquisition of Green Valley Pharmaceutical for 1.412 billion yuan has unexpectedly led to a decline in the company's stock price and a regulatory inquiry from the Shanghai Stock Exchange [2]. Group 1: Acquisition Details - The acquisition involves a combination of "acquiring existing equity + subscribing to new registered capital," with the payment structured in installments: an initial payment of 635 million yuan at the time of closing, followed by another 635 million yuan within three years based on the target company's R&D progress [3]. - Fosun Pharma aims to secure the rights to the main product, the mannitol sodium capsule, which has faced efficacy controversies since its conditional approval in November 2019 for treating mild to moderate Alzheimer's disease [2][3]. Group 2: Clinical Trial and Regulatory Aspects - The mannitol sodium capsule's commercial production is contingent upon completing ongoing post-marketing confirmatory clinical trials and obtaining approval from the National Medical Products Administration (NMPA) [4]. - Fosun Pharma has not identified any unresolved core technical issues or substantial obstacles in advancing the confirmatory clinical trials [4]. - The revised clinical trial protocol, which extends the double-blind treatment period from 36 weeks to 48 weeks and increases the sample size from 1,312 to 1,950 participants, has been approved by the NMPA [5]. - As of December 15, 2025, 580 participants have been enrolled in the clinical study, with projections indicating that all participants could be enrolled by the end of 2027 and data could be available by early 2029 [5].

Core Viewpoint - The acquisition of Green Valley Pharmaceutical by Fosun Pharma has led to a significant decline in the company's stock price and regulatory scrutiny, primarily due to concerns surrounding the clinical efficacy and commercialization of the Alzheimer's drug, Manluotena Capsules [1][2]. Group 1: Acquisition Details - Fosun Pharma plans to acquire Green Valley Pharmaceutical for a total of 14.12 billion yuan, using a combination of stock transfer and subscription to new registered capital, with payments made in installments [2]. - The first payment of 635 million yuan will be made on the closing date, with the remaining amount to be paid over three years based on the target company's R&D progress [2]. - The founder-controlled entity of the target company will pledge 10% of its shares to provide collateral for potential risks, enhancing the security of the transaction [2]. Group 2: Clinical Trial Progress - Manluotena Capsules, initially approved in November 2019, have faced efficacy controversies and require completion of post-marketing confirmatory clinical trials to resume commercialization [1][2]. - The clinical trial protocol has been revised to extend the double-blind treatment period from 36 weeks to 48 weeks and increase the sample size from 1,312 to 1,950 participants, in accordance with the latest guidelines from the National Medical Products Administration [3]. - As of December 15, 2025, 580 participants have been enrolled in the clinical study, with projections indicating that enrollment will be completed by the end of 2027 and data readout by early 2029 [4].

Core Viewpoint - A controversial Alzheimer's drug, known as "971," has regained the possibility of being sold after a recent acquisition by Fosun Pharma, which plans to invest approximately 1.412 billion yuan to acquire 51% of Green Valley Pharmaceutical [1][2]. Group 1: Acquisition and Financial Implications - Fosun Pharma's acquisition of Green Valley Pharmaceutical marks the first purchase under the leadership of newly appointed Chairman Chen Yuqing [2]. - The market reacted negatively to the acquisition, with Fosun Pharma's A-shares dropping by 4.22% and Hong Kong shares by 5.81% on December 16 [2]. - The acquisition is expected to have a minimal impact on Fosun Pharma's financial statements in the coming years, as Green Valley will focus on clinical trials post-acquisition [10]. Group 2: Drug Development and Clinical Trials - Fosun Pharma aims to complete post-marketing confirmatory clinical trials for 971, with an optimistic timeline for approval in the first half of 2029 and potential inclusion in medical insurance by 2030 [2][3]. - The estimated cost for domestic Phase III clinical trials is around 685 million yuan, with plans for international multi-center trials if suitable conditions arise [3]. - The target patient population for 971 is approximately 3.56 million, with a projected market penetration rate of 22% [4]. Group 3: Controversies and Efficacy Concerns - The drug's efficacy has been heavily criticized, with notable academic figures questioning its mechanism and clinical trial data [6][7]. - Despite the controversies, there is a significant demand for the drug, with prices reportedly reaching 1,600 to 2,400 yuan, significantly higher than its previous insurance-covered price [8]. - Clinical data from over 800 patients reportedly shows that 971 performs better than a placebo, and there is a growing body of real-world evidence supporting its effectiveness [7]. Group 4: Company Background and Future Prospects - Green Valley Pharmaceutical, founded by Lü Songtao, has faced scrutiny in the past, including allegations of fraudulent claims regarding its products [9][10]. - The company reported revenues of 572 million yuan in 2024, but faced significant losses in the first nine months of 2025 due to the suspension of 971 [10]. - Following the acquisition, Green Valley will operate as a subsidiary of Fosun Pharma, with a focus on completing necessary clinical trials to regain market approval [10].

Core Viewpoint - The recent acquisition of a 51% stake in Green Valley Pharmaceutical by Fosun Pharma aims to revive the controversial Alzheimer's drug, 甘露特钠胶囊 (known as "971"), which had previously faced significant skepticism regarding its efficacy and was halted due to unmet post-marketing clinical trial requirements [1][2][5]. Group 1: Acquisition Details - Fosun Pharma announced an investment of approximately 1.412 billion yuan to acquire a 51% stake in Green Valley Pharmaceutical [1]. - This acquisition marks the first major move by the newly appointed chairman of Fosun Pharma, Chen Yuqing, since taking office in April 2025 [2]. - Following the announcement, Fosun Pharma's stock experienced a decline, with a drop of 4.22% in A-shares and 5.81% in Hong Kong shares on December 16 [2]. Group 2: Clinical Trial Plans - Fosun Pharma plans to conduct post-marketing confirmatory clinical trials for 971, with the goal of obtaining approval by mid-2029 and entering medical insurance by 2030 [2][3]. - The estimated cost for the domestic Phase III clinical trials is around 685 million yuan, with plans for potential international multi-center trials if conditions are favorable [3]. - The clinical trial aims to enroll over 1,900 patients and will adhere to the guidelines set by the National Medical Products Administration [3]. Group 3: Market Potential - The target population for 971 is estimated to be around 3.56 million, with a projected market penetration rate of 22% [4]. - If approved by mid-2029 and included in medical insurance by 2030, the peak sales for 971 are expected to reach approximately 4 billion yuan by 2035 [4]. - In a scenario where the drug is not included in medical insurance, sales in 2030 are anticipated to exceed 1 billion yuan [4]. Group 4: Efficacy Controversies - The efficacy of 971 has been heavily debated, with notable criticisms regarding its mechanism of action and clinical trial data [5][6]. - Despite the controversies, Fosun Pharma maintains confidence in the drug's effectiveness, citing data from over 800 patients showing that 971 outperformed placebo [6]. - The drug's commercial value remains significant, with patients reportedly seeking it at prices significantly higher than previous insurance-covered rates [8]. Group 5: Company Background - Green Valley Pharmaceutical, founded by Lü Songtao in 2018, has faced scrutiny due to past controversies surrounding its products [9][10]. - The company reported revenues of 572 million yuan in 2024, but faced significant losses in 2025 due to the suspension of 971 [10]. - Following the acquisition, Green Valley will operate as a subsidiary of Fosun Pharma, with its future clinical trial efforts being a core focus [10].

Core Viewpoint - Fosun Pharma is optimistic about the potential of the Alzheimer's drug "971," expecting it to complete clinical trials by the end of 2028, receive approval in the first half of 2029, and enter health insurance by 2030, with peak sales projected to reach approximately 4 billion yuan by 2035 [1][2][5]. Group 1: Acquisition and Financial Implications - Fosun Pharma announced plans to invest approximately 1.412 billion yuan to acquire a 51% stake in Green Valley Pharmaceutical, known for the drug "971" [2]. - Following the acquisition announcement, Fosun Pharma's stock fell by 4.22% in A-shares and 5.81% in Hong Kong, indicating market skepticism regarding the decision [3]. - The overall cost for the domestic Phase III clinical trial is estimated to be 685 million yuan, with additional funding planned based on progress [6]. Group 2: Clinical Trial and Regulatory Path - The clinical trial for "971" will be conducted in collaboration with Green Valley Pharmaceutical, with a target of enrolling over 1,900 patients [6][7]. - The expected timeline for completing the registration-confirmatory Phase III clinical trial is by the end of 2028, with a streamlined approval process anticipated to take about 5 to 6 months [6][7]. - The drug's target patient population is estimated to be around 3.56 million, with a market penetration rate projected at 22% [7]. Group 3: Efficacy Controversies - The efficacy of "971" has faced significant scrutiny, with notable criticisms from scholars regarding its mechanism of action and clinical trial data [9][11]. - Despite the controversies, Fosun Pharma maintains confidence in the drug's effectiveness, citing clinical data from over 800 patients that reportedly show better results than placebo [9][12]. - The drug's commercial potential remains strong, with high demand leading to inflated prices in the market, significantly above previous insurance prices [12][13]. Group 4: Company Background and Future Outlook - Green Valley Pharmaceutical, founded by Lü Songtao, has a history of controversial products, but "971" has been a focal point of its business strategy [15][16]. - Following the acquisition, Green Valley will become a subsidiary of Fosun Pharma, with its future operations primarily focused on clinical trials [16]. - The financial impact of Green Valley's operations on Fosun Pharma's overall financials is expected to be minimal in the short term, as the focus will be on completing the necessary clinical work [16].

Core Viewpoint - A controversial Alzheimer's drug, known as "971," has regained the possibility of being marketed after a significant investment by Fosun Pharma, despite ongoing skepticism regarding its efficacy [2][3]. Company Summary - Fosun Pharma announced plans to invest approximately 1.412 billion yuan to acquire a 51% stake in Green Valley (Shanghai) Pharmaceutical Technology Co., known for the drug "971" [3]. - The drug was conditionally approved in China in 2019, marking the first Alzheimer's drug to enter the market in 17 years, with sales of over 2 million boxes expected in 2024 [3][13]. - Due to the failure to complete post-marketing confirmatory clinical trials, the National Medical Products Administration (NMPA) did not approve the drug's reapplication in 2025, leading to its suspension [3][5]. - Fosun Pharma's management expressed confidence in the drug's efficacy and plans to conduct the necessary clinical trials to seek reapproval by 2029, with peak sales projected to reach around 4 billion yuan by 2035 [3][5][8]. Clinical Trial and Regulatory Summary - The company aims to complete the post-marketing confirmatory clinical trials, which are estimated to cost around 685 million yuan, and will involve over 1,900 patients [6][7]. - The trials will assess cognitive and functional outcomes in accordance with international standards, with completion expected by the end of 2028 [7][10]. - Fosun Pharma has already discussed a new plan with the NMPA to meet drug registration requirements [6][8]. Market Reaction and Financial Impact - The market reacted negatively to the acquisition announcement, with Fosun Pharma's stock dropping by 4.22% in A-shares and 5.81% in Hong Kong shares on December 16 [3]. - The estimated target population for the drug is around 3.56 million, with a projected market penetration rate of 22% [8][10]. - If the drug is approved in the first half of 2029 and enters insurance coverage by 2030, peak sales could reach approximately 4 billion yuan; if delayed, sales could still exceed 1 billion yuan in 2030 [8][10]. Controversy and Efficacy Concerns - The drug's efficacy has been heavily criticized, with notable academic figures questioning its mechanism and clinical trial data [9][10]. - Despite the controversies, there is a significant demand for the drug, with prices in the market reportedly reaching 1,600 to 2,400 yuan, significantly higher than its previous insurance price [11][12]. - The ongoing debate about the drug's effectiveness continues to influence investor sentiment and market dynamics [9][10].